Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial
Merck emphasized the broader significance of the findings
Merck emphasized the broader significance of the findings
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Subscribe To Our Newsletter & Stay Updated